Botulinum Toxin: Does it have a Place in the Management of Depression?
“‘Cause when you worry your face will frown/And that will bring everybody down/So don’t worry, be happy.” This bit of pop pathophysiology, sung by Bobby McFerrin in the 1988 Grammy Song of the Year , has in the past dozen years been taken quite literally in some quarters at the interface of dermatology and psychiatry. The hypothesis is that, by using targeted intramuscular injections of botulinum toxin, type A (onabotulinumtoxinA, BTX-A, Botox) to pharmacologically block frowning, and the associated muscle contractions that lead—along with age—to “worry lines” and facial wrinkles, depression could actually be treated and reversed. This so-called “facial feedback” hypothesis traces back to great nineteenth century thinkers, including Charles Darwin (“repression … of all outward signs softens our emotions”)  and William James (“refuse to express a passion, and it dies”) , and has evolved into a theory of “emotional proprioception” , positing that the muscles of facial...
The opinions expressed in this article are solely those of the author and do not purport to represent the official position or policy of the US National Institutes of Health or Department of Health and Human Services.
This work was prepared by Dr. Matthew V. Rudorfer in his capacity as an employee and officer of the U.S. Government, with no external funding.
Compliance with Ethical Standards
Conflicts of Interest
Dr. Matthew V. Rudorfer has no conflicts of interest.
- 1.Recording Academy. Artist: Bobby McFerrin. https://www.grammy.com/grammys/artists/bobby-mcferrin. Accessed 5 Jan 2018.
- 3.James W. The principles of psychology. New York: Henry Holt and Company; 1890.Google Scholar
- 6.Wollmer MA, de Boer C, Kalak N, Beck J, Götz T, Schmidt T, Hodzic M, Bayer U, Kollmann T, Kollewe K, Sönmez D, Duntsch K, Haug MD, Schedlowski M, Hatzinger M, Dressler D, Brand S, Holsboer-Trachsler E, Kruger TH. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012;46:574–81.CrossRefPubMedGoogle Scholar
- 9.Patel S. OnabotulinumtoxinA as treatment for major depressive disorder in adult females. 2017. https://clinicaltrials.gov/show/NCT02116361. Accessed 31 Mar 2017.
- 10.Allergan press release. Allergan reports topline Phase II data supporting advancement of BOTOX® (onabotulinumtoxinA) for the treatment of major depressive disorder (MDD). https://www.allergan.com/News/News/Thomson-Reuters/Allergan-Reports-Topline-Phase-II-Data-Supporting. Accessed 4 May 2017.
- 12.Saunders B. CEO blog: mental illness—a growing problem that needs our focus. 2016. https://www.allergan.com/news/ceo-blog/may-2016/mental-illness. Accessed 25 May 2016.
- 14.Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2017. https://doi.org/10.1176/appi.ajp.2017.17040472.PubMedCentralGoogle Scholar
- 15.Hennenlotter A, Dresel C, Castrop F, Ceballos-Baumann AO, Wohlschläger AM, Haslinger B. The link between facial feedback and neural activity within central circuitries of emotion—new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex. 2009;19:537–42.CrossRefPubMedGoogle Scholar